Pemphigus Vulgaris - Pipeline Review, H2 2020

Pemphigus Vulgaris - Pipeline Review, H2 2020


latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2020, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Introduction
Pemphigus Vulgaris- Overview
Pemphigus Vulgaris- Therapeutics Development
Pemphigus Vulgaris- Therapeutics Assessment
Pemphigus Vulgaris- Companies Involved in Therapeutics Development
Pemphigus Vulgaris- Drug Profiles
Pemphigus Vulgaris- Dormant Projects
Pemphigus Vulgaris- Discontinued Products
Pemphigus Vulgaris- Product Development Milestones
Appendix

List Of Tables

Number of Products under Development for Pemphigus Vulgaris, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pemphigus Vulgaris - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Pemphigus Vulgaris - Pipeline by Argenx SE, H2 2020
Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2020
Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, H2 2020
Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, H2 2020
Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Pemphigus Vulgaris - Pipeline by Declion Pharmaceuticals Inc, H2 2020
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H2 2020
Pemphigus Vulgaris - Pipeline by iBio Inc, H2 2020
Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2020
Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, H2 2020
Pemphigus Vulgaris - Pipeline by Pharmapraxis, H2 2020
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H2 2020
Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, H2 2020
Pemphigus Vulgaris - Dormant Projects, H2 2020
Pemphigus Vulgaris - Discontinued Products, H2 2020

List Of Figures

Number of Products under Development for Pemphigus Vulgaris, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

Fill The Form For Sample Request

There is no Reviews available